Patents Examined by Shawquia Jackson
-
Patent number: 11680044Abstract: An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.Type: GrantFiled: September 26, 2022Date of Patent: June 20, 2023Assignee: Beckley Psytech LimitedInventors: Cosmo Feilding-Mellen, Timothy Mason
-
Patent number: 11680051Abstract: The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.Type: GrantFiled: August 30, 2021Date of Patent: June 20, 2023Assignee: Aurigene Discovery Technologies LimitedInventors: Pottayil Govindan N. Sasikumar, Seetharamaiah Setty S. Naremaddepalli
-
Patent number: 11680043Abstract: The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.Type: GrantFiled: March 30, 2022Date of Patent: June 20, 2023Assignee: Eleusis Therapeutics US, Inc.Inventors: David E. Nichols, Graham Johnson, Hooshang S. Zavareh, Claire Wombwell, Daniel Rixson, Peter Haddow, Carrie Sheard, Alexander Schwarz
-
Patent number: 11679109Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: December 23, 2020Date of Patent: June 20, 2023Assignee: Kymera Therapeutics, Inc.Inventors: Yi Zhang, Paul R. Fleming, Xiao Zhu
-
Patent number: 11667607Abstract: The present disclosure provides a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. Solvent screen, X-ray powder diffractogram, thermogravimetric mass spectroscopy, differential scanning calorimetry, 1H-NMR, dynamic vapor sorption, and UPLC data on each of the crystalline forms is presented, along with methods preparing each of the crystalline forms.Type: GrantFiled: September 12, 2022Date of Patent: June 6, 2023Assignee: Zylorion Health Inc.Inventor: Peter Silverstone
-
Patent number: 11667644Abstract: Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.Type: GrantFiled: July 9, 2021Date of Patent: June 6, 2023Assignee: Janssen Pharmaceutica NVInventors: Wenying Chai, Michael A. Letavic, Kiev S. Ly, Daniel J. Pippel, Dale A. Rudolph, Kathleen C. Sappey, Brad M. Savall, Chandravadan R. Shah, Brock T. Shireman, Akinola Soyode Johnson, Emily M. Stocking, Devin M. Swanson
-
Patent number: 11666546Abstract: GHB drug delivery systems comprising a floating interpenetrating network (IPN) are provided. The pharmaceutical compositions contain at least one IPN forming system, at least GHB drug, and at least one gas generating agent, such that upon oral ingestion of the compositions, a floating IPN is formed in situ. These floating IPN provide extended release of the GHB drug entrapped therein for at least about 3 hours.Type: GrantFiled: December 18, 2018Date of Patent: June 6, 2023Assignee: TRIS PHARMA, INCInventors: Paras Rameshlal Jain, Sachin Vasant Chaudhari
-
Patent number: 11660289Abstract: The present invention relates to compounds of formula (I) as defined herein, which comprise a greater proportion of deuterium to protium than naturally found in hydrogen; and compositions, including pharmaceutical compositions, comprising these compounds and optionally analogous compounds of formula (I), which are not deuterium-enriched. These compounds and compositions are of use in therapy, in particular in the treatment of psychiatric or neurological disorders. Varying the amounts of the different compounds within the compositions of the invention allows tailoring of the compositions' therapeutic effects. A particularly efficient synthetic method which enables compounds of formula (I) and related compounds of formula (I?) is also provided.Type: GrantFiled: February 25, 2022Date of Patent: May 30, 2023Assignee: SMALL PHARMA LTD.Inventors: Peter Rands, Ellen James, Tiffanie Benway, Zelah Joel, Marie Layzell
-
Patent number: 11661419Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.Type: GrantFiled: December 18, 2020Date of Patent: May 30, 2023Assignee: Pfizer Inc.Inventors: Scott William Bagley, Agustin Casimiro-Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
-
Patent number: 11655220Abstract: A process is disclosed for preparing sartan drugs including intermediates thereof, which avoids formation of Nitrosoamine impurities.Type: GrantFiled: April 7, 2021Date of Patent: May 23, 2023Assignee: Hetero Labs LimitedInventors: Kura Rathnakar Reddy, Nagabelli Murali, Nimmanapalli Pullareddy
-
Patent number: 11643401Abstract: The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.Type: GrantFiled: June 17, 2021Date of Patent: May 9, 2023Assignee: Curis, Inc.Inventor: Shu Yu
-
Patent number: 11641777Abstract: An object is to provide a novel organic compound. Another object is to provide a novel light-emitting device. Another object is to provide a light-emitting device with favorable emission efficiency. Another object is to provide a light-emitting device with a favorable lifetime. Another object is to provide a light-emitting device with a low driving voltage. A dibenzo[c,g]carbazole derivative represented by the following general formula (G1) and a light-emitting device using it are provided. Note that at least one of R11 to R22 represents a substituent that has 14 to 60 carbon atoms in total and contains a condensed tricyclic to hexacyclic aromatic hydrocarbon skeleton, and the others independently represent any of hydrogen, an alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, and a substituted or unsubstituted aryl group having 6 to 25 carbon atoms.Type: GrantFiled: November 12, 2018Date of Patent: May 2, 2023Inventors: Hiroshi Kadoma, Tsunenori Suzuki, Naoaki Hashimoto, Yusuke Takita, Satoshi Seo
-
Patent number: 11639354Abstract: One of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity. Another of the purposes of the present invention is to provide a heterocyclic derivative that has an IAP (particularly XIAP) binding (inhibiting) activity and exhibits a protein degradation induction activity. The present invention provides a compound represented by formula (I) (the symbols in the formula are as defined in the present Description) and salts thereof.Type: GrantFiled: July 31, 2019Date of Patent: May 2, 2023Assignee: FIMECS, INC.Inventors: Yusuke Tominari, Yoshihide Tomata, Kanae Gamo, Naomi Kitamoto
-
Patent number: 11634397Abstract: The invention provides a process for preparing heterocyclic fluoroalkenyl sulfones and their thioether and sulfoxide precursors of the formula: Cl—R—S(O)n—(CH2)2—CF?CF2 (Formula I?) wherein R is a heterocyclic five-membered aromatic ring and n is 0, 1 or 2, comprising a step of dehalogenation of a compound of the formula: Cl—R—S(O)n—(CH2)2—CFX1—CF2X2 (Intermediate B), wherein X1 and X2 are independently halogen atoms, to remove said X1 and X2 atoms. Also included are novel intermediate compounds.Type: GrantFiled: September 26, 2019Date of Patent: April 25, 2023Assignee: ADAMA MAKHTESHIM LTD.Inventors: Thomas Zell, Shlomi Cohen
-
Patent number: 11634389Abstract: Provided herein are compounds of Formula (I), including methods of making the same. The disclosed compounds are succinate dehydrogenase inhibitors and can be useful in, e.g., inhibiting or preventing fungal growth.Type: GrantFiled: November 13, 2019Date of Patent: April 25, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Corey Stephenson, Daryl Staveness
-
Patent number: 11634387Abstract: This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutically acceptable carrier or vehicle. The compounds and compositions disclosed herein are useful for treating or preventing various diseases and conditions, for example liver disease such as liver fibrosis, fatty liver disease, non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), and kidney diseases such as acute kidney injury (AKI).Type: GrantFiled: March 31, 2021Date of Patent: April 25, 2023Assignee: Abionyx Pharma SAInventor: Jean-Louis Henri Dasseux
-
Patent number: 11634392Abstract: A high yielding extraction process for the purification of N-(2,4-dichloro-5-(4-(difluoromethyl)-3-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methanesulfonamide (sulfentrazone) by selectively partitioning the desired product from the crude mixture, thereby increasing its purity by decreasing the presence of unwanted impurities and improving the color and particle size distribution of the final sulfentrazone product. The selective partitioning is achieved by the sequential use of an organic solvent, water, aqueous inorganic base and a concentrated aqueous inorganic acid.Type: GrantFiled: October 6, 2020Date of Patent: April 25, 2023Assignee: Tagros Chemicals India Pvt LtdInventors: Bomi P Framroze, Rajaiah Shrikrishnan, Rajagopal Kuppuswamy
-
Patent number: 11633485Abstract: A co-drug according to Formula (I) or Formula (II) is provided, R—X—NH—CO—CO—OR1??(I) R—X—CO—O—CH2—CO—OR1??(II) wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—OR1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.Type: GrantFiled: March 13, 2018Date of Patent: April 25, 2023Assignee: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Michael Chorny, Garrett M. Brodeur
-
Patent number: 11632958Abstract: Described is the use of compositions comprising a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram and a fungicide selected from the group of phosphonates, in particular fosetyl-aluminium for controlling Mosaic scab and reducing Venturia inequalis inoculum in apples, to a method for treating apple plants or apple plant parts for controlling Mosaic scab scab and reducing Venturia inequalis inoculum in apples and to a method for controlling Mosaic scab scab and reducing Venturia inequalis inoculum in plants and plant parts, in particular leaves by treating them with compositions comprising a fungicide selected from the group of succinate dehydrogenase inhibitors, in particular fluopyram and a fungicide selected from the group of phosphonates, in particular fosetyl-aluminium.Type: GrantFiled: December 17, 2018Date of Patent: April 25, 2023Assignee: Bayer AktiengesellschaftInventors: Sybille Lamprecht, Luk De Maeyer, Gilbert Labourdette
-
Patent number: 11634412Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: January 15, 2021Date of Patent: April 25, 2023Assignee: Raze Therapeutics, Inc.Inventor: Nello Mainolfi